Isoket®

Active ingredient Isosorbiddinitrate (ISDN) Mode of action Isosorbide dinitrate belongs to the group of nitrates from which nitric oxide (NO) can be released after absorption into the body. Nitric oxide leads to dilation of blood vessels (vasodilation), especially of the veins and larger coronary arteries. Nitrates thus lead to a reduction in the so-called preload, … Isoket®

Contraindications | Isoket®

Contraindications Isosorbide dinitrate must not be used in cases of known hypersensitivity to the active substance, acute circulatory failure, cardiogenic shock, systolic blood pressure < 90 mmHg (hypotension), hypertrophic obstructive cardiomyopathy (HOCM), and narrowing of the mitral valve or aortic valve (stenosis). Interactions A combination of ISDN and drugs to treat erectile dysfunction from the … Contraindications | Isoket®

Nitric Oxide

Products Nitric oxide is commercially available as a gas for medical use (inhalation gas). It has been approved since 1999. Structure and properties Nitric oxide (NO, Mr = 30.0 g/mol) exists as a colorless gas that turns brown in air. It is a free radical. Nitrogen dioxide forms rapidly in air. Structure: -N=O Effects Nitric … Nitric Oxide

Pentalong®

Active ingredient: pentaerythrityl tetranitrateThe active ingredient belongs to the group of vasodilating substances (nitrates) and is used to promote blood flow to the heart in the case of constricted coronary arteries. In the organism, the active ingredient is broken down into the body’s own nitrogen monoxide (NO). This has a direct dilating effect on the … Pentalong®

Interactions | Pentalong®

Interactions When taking other medications in addition to Pentalong®, it must be noted that the effect of the medication may be intensified. This applies, for example, to the simultaneous intake of beta blockers, calcium channel blockers, diuretics, ACE inhibitors, phosphodiesterase inhibitors, certain antidepressants and neuroleptics, as well as alcohol consumption. Pentalong® also weakens the effect … Interactions | Pentalong®

Background | Pentalong®

Background Pentalong® was developed in the USA in the 1950s. Since 1964 it was produced in the former GDR by a Zwickau company. Today the company Actavis holds the rights to Pentalong®. However, since the drug never had to go through an approval procedure, Actavis had to apply for a subsequent approval. This was the … Background | Pentalong®